Disturbances in microvascular perfused boundary region and plasma levels of syndecan-1 and heparan sulfate in cardiopulmonary resuscitated patients during re-warming phase of therapeutic hypothermia treatment.

Disturbances in microvascular perfused boundary region and plasma levels of syndecan-1 and heparan sulfate in cardiopulmonary resuscitated patients during re-warming phase of therapeutic hypothermia treatment. - Microvasculature during therapeutic hypothermia (VASCA)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38597

Enrollment

Registered

2013-10-30

Start date

2013-11-21

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac arrest

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * age *18 years * out-of hospital cardiac arrest with spontaneous return of circulation * undergoing mild therapeutic hypothermia * admittance to the intensive care unit * written informed/deferred consent

Exclusion criteria

Exclusion criteria: * severe traumatic brain injury * cardiac arrest due to submersion * infection already present before collapse * moribund patients

Design outcomes

Primary

Measure	Time frame
Determine whether and to what extent changes in microvascular PBR, as measure for glycocalyx damage, occur in survivors and non-survivors of CA during the re-warming phase of therapeutic hypothermia treatment.	—

Secondary

Measure	Time frame
- Determine whether and to what extent changes in syndecan-1 and heparan sulfate plasma levels, as measure for glycocalyx damage, occur in survivors and non-survivors of CA during the re-warming phase of therapeutic hypothermia treatment. - Determine the association of syndecan-1 and heparan sulfate plasma levels with the PBR in post-CA patients during the re-warming phase of therapeutic hypothermia treatment. - Determine whether and to what extent changes in microcirculatory perfused vessel density (PVD) and mean flow index (MFI) occur in survivors and non-survivors of CA during the re-warming phase of therapeutic hypothermia treatment.	—

Measure

Time frame

- Determine whether and to what extent changes in syndecan-1 and heparan sulfate plasma levels, as measure for glycocalyx damage, occur in survivors and non-survivors of CA during the re-warming phase of therapeutic hypothermia treatment. - Determine the association of syndecan-1 and heparan sulfate plasma levels with the PBR in post-CA patients during the re-warming phase of therapeutic hypothermia treatment. - Determine whether and to what extent changes in microcirculatory perfused vessel density (PVD) and mean flow index (MFI) occur in survivors and non-survivors of CA during the re-warming phase of therapeutic hypothermia treatment.

—

Countries

Netherlands

Outcome results